24/7 Wall Street
04 Sept 2026, 14:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
Patent settlements have pushed the earliest generic entry for Biktarvy, Gilead's primary revenue driver, to April 2036. — Extending the exclusivity of a blockbuster drug by a decade provides long-term revenue certainty and removes immediate 'patent cliff' fears.
+0.60Gilead's fiscal 2025 free cash flow of approximately $9.45 billion covered its $4 billion dividend payout more than twice over. — Strong dividend coverage reduces the risk of payout cuts, making the stock more attractive to income-focused investors.
+0.40Gilead is diversifying revenue through growth in PrEP sales, which exceeded $1 billion in a quarter, and Trodelvy oncology revenue, which is approaching a $2 billion run rate. — Reducing reliance on a single HIV drug mitigates long-term concentration risk and creates new growth vectors.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
The company reported a second-quarter net loss of $10.496 billion due to $11.2 billion in acquired in-process R&D charges from recent deals. — While these are accounting charges, they highlight high acquisition costs and a significant reduction in shareholder equity.
-0.20Gilead's cell therapy franchise revenue declined 14% year-over-year due to increased competition. — Loss of market share in a key growth area suggests competitive headwinds in the oncology/cell therapy pivot.
-0.20Which stocks this story touches
Strong cash flow, growing dividends, and extended patent protection for its blockbuster drug Biktarvy offset long-term concentration risks.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
41m ago
